IMTX Latest Press Releases

-- December 11, 2025 --

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress Globe Newswire 7:00 AM

-- December 5, 2025 --

Immatics Announces $125 Million Underwritten Offering Globe Newswire 6:00 AM

-- November 17, 2025 --

Immatics Announces Third Quarter 2025 Financial Results and Business Update Globe Newswire 7:00 AM

-- November 12, 2025 --

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps Globe Newswire 7:00 AM

-- October 27, 2025 --

Immatics Appoints Amie Krause as Chief People Officer Globe Newswire 7:00 AM

-- October 20, 2025 --

Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium Globe Newswire 10:30 AM

-- October 1, 2025 --

Immatics Appoints Venkat Ramanan as Chief Financial Officer Globe Newswire 7:00 AM

-- August 13, 2025 --

Immatics Announces Second Quarter 2025 Financial Results and Business Update Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software